Researchers at Memorial Sloan Kettering Cancer Center, New York, have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib.
Kidney organoids provide a promising platform in vitro to model the mechanisms of kidney disease, however, they are limited by an existing lack of knowledge of their inherent functional protein expression. In a new report ...
Knowing whether a tumor might grow or spread to other parts of a patient's body could be key to survival—and now scientists are one step closer to unlocking the ability to predict just that.
Apr 13, 2023
0
72
A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer, according to new research directed by investigators at the Johns Hopkins ...
17 hours ago
0
0
Cancer cells salvage purine nucleotides to fuel tumor growth, including purines in foods we eat, an important discovery with implications for cancer therapies from research by Children's Medical Center Research Institute ...
Jul 19, 2024
0
20
Immune system cells called macrophages play an unexpected role in the complicated connection between obesity and cancer, a Vanderbilt University Medical Center-led research team has discovered.
Jun 12, 2024
0
24
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 million people worldwide, ...
Jan 22, 2024
1
46
A growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new hope by mobilizing their immune systems against tumor cells. An emerging class of such immunotherapeutics, ...
Aug 23, 2023
0
36
While Wilms tumor—also known as nephroblastoma—is rare, it is the most prevalent childhood kidney cancer. Researchers at Children's Hospital Los Angeles have now pinpointed a disruption in early kidney progenitor cell ...
May 1, 2023
0
83
The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict—before treatment begins—how well ...
Apr 6, 2023
0
84
